A Phase 1 interventional study of Povorcitinib and Ruxolitinib in Healthy Participants, sponsored by Incyte Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the interstitial concentrations using the open-flow microperfusion device and plasma pharmacokinetics following multiple doses of povorcitinib or topical ruxolitinib cream in healthy adult participants.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined Inclusion/Exclusion Criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib cream applied topically twice daily.
Drug: Ruxolitinib
Povorcitinib will be administered at the protocol defined dose.
Drug: Povorcitinib
Povorcitinib will be administered at the protocol defined dose.
Drug: Povorcitinib
Oral; Tablet
Also known as: INCB054707
Ruxolitinib cream applied topically.
Pharmacokinetics Parameter (PK): Cmax of dermal interstitial fluid (dISF) ruxolitinib
Defined as the maximum observed plasma concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: AUClast of dISF ruxolitinib
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: AUC∞ of dISF ruxolitinib
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Time frame: Up to Day 12
Pharmacokinetics Parameter: Cmax of dISF povorcitinib
Defined as the maximum observed plasma concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: AUClast of dISF povorcitinib
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: AUC∞ of dISF povorcitinib
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Time frame: Up to Day 12
Pharmacokinetics Parameter: Cmax of plasma ruxolitinib
Defined as the maximum observed plasma concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: AUClast of plasma ruxolitinib
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: AUC∞ of plasma ruxolitinib
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Time frame: Up to Day 12
Pharmacokinetics Parameter: Cmax of plasma povorcitinib
Defined as the maximum observed plasma concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: AUClast of plasma povorcitinib
Defined as the area under the concentration-time curve from time zero to the last quantifiable concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: AUC∞ of plasma povorcitinib
Defined as the area under the plasma concentration-time curve extrapolated to time of infinity.
Time frame: Up to Day 12
Number of participants with Treatment-emergent Adverse Events (TEAEs)
Defined as any adverse event, either reported for the first time or the worsening of a pre-existing event, occurring after first dose of study treatment.
Time frame: Up to Day 28
Pharmacokinetics Parameter: tmax of dISF ruxolitinib
Defined as the time to maximum concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: t½ of dISF ruxolitinib
Defined as the apparent terminal-phase disposition half-life.
Time frame: Up to Day 12
Pharmacokinetics Parameter: CL/F of dISF ruxolitinib
Defined as the apparent clearance.
Time frame: Up to Day 12
Pharmacokinetics Parameter: Vz/F of dISF ruxolitinib
Defined as the apparent volume of distribution.
Time frame: Up to Day 12
Pharmacokinetics Parameter: λz of dISF ruxolitinib
Defined as the terminal-phase disposition rate constant.
Time frame: Up to Day 12
Pharmacokinetics Parameter: tmax of dISF povorcitinib
Defined as the time to maximum concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: t½ of dISF povorcitinib
Defined as the apparent terminal-phase disposition half-life.
Time frame: Up to Day 12
Pharmacokinetics Parameter: CL/F of dISF povorcitinib
Defined as the apparent clearance.
Time frame: Up to Day 12
Pharmacokinetics Parameter: Vz/F of dISF povorcitinib
Defined as the apparent volume of distribution.
Time frame: Up to Day 12
Pharmacokinetics Parameter: λz of dISF povorcitinib
Defined as the terminal-phase disposition rate constant.
Time frame: Up to Day 12
Pharmacokinetics Parameter: tmax of plasma ruxolitinib
Defined as the time to maximum concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: t½ of plasma ruxolitinib
Defined as the apparent terminal-phase disposition half-life.
Time frame: Up to Day 12
Pharmacokinetics Parameter: CL/F of plasma ruxolitinib
Defined as the apparent clearance.
Time frame: Up to Day 12
Pharmacokinetics Parameter: Vz/F of plasma ruxolitinib
Defined as the apparent volume of distribution.
Time frame: Up to Day 12
Pharmacokinetics Parameter: λz of plasma ruxolitinib
Defined as the terminal-phase disposition rate constant.
Time frame: Up to Day 12
Pharmacokinetics Parameter: tmax of plasma povorcitinib
Defined as the time to maximum concentration.
Time frame: Up to Day 12
Pharmacokinetics Parameter: t½ of plasma povorcitinib
Defined as the apparent terminal-phase disposition half-life.
Time frame: Up to Day 12
Pharmacokinetics Parameter: CL/F of plasma povorcitinib
Defined as the apparent clearance.
Time frame: Up to Day 12
Pharmacokinetics Parameter: Vz/F of plasma povorcitinib
Defined as the apparent volume of distribution.
Time frame: Up to Day 12
Pharmacokinetics Parameter: λz of plasma povorcitinib
Defined as the terminal-phase disposition rate constant.
Time frame: Up to Day 12
Plan to share: No
Ran from May 2026 to primary completion in Sep 2026, 3 months.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 9, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Povorcitinib · Ruxolitinib